Sophiris Bio Inc. is a clinical-stage biopharmaceutical company focused on developing products for the treatment of urological diseases. The Company is developing PRX302 as a treatment for the lower urinary tract symptoms of benign prostatic hyperplasia, or BPH, commonly referred to as an enlarged prostate and as a treatment for localized low to intermediate risk prostate cancer. PRX302, a genetically modified recombinant protein, is delivered via ultrasound-guided injection directly into the prostate. The Company completed placebo-controlled Phase IIb clinical trial of PRX302 for BPH symptoms. The Company is also engaged in the ongoing and planned clinical development in BPH and localized prostate cancer for PLUS-1, a Phase III clinical trial of PRX302 for the treatment of the lower urinary tract symptoms of BPH.